In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

Though the baseline illness severity was uneven, with more severe patients in the itolizumab arm, the medication showed great effectiveness when compared to the generally used standard-of-care therapy ...

Shares of Equillium (NASDAQ:EQ) soared 26% Thursday after the company and partner Biocon reported positive topline results from a Phase 2 study of the drug itolizumab in the treatment of moderate to ...

This week’s Bulls N’ Bears Runner of the Week is… Kalgoorlie Gold Mining. The company’s share price rocketed after a new ...

Equillium, Inc. (NASDAQ:EQ), a biotechnology company with a market capitalization of $25.15 million and current stock price of $0.71, announced today the positive outcomes of their Phase 2 clinical ...

Equillium, Inc. , a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, and ...

Equillium (EQ) and Biocon announced topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ...

Mikko Koskimies, CEO of eQ Plc and Managing Director of eQ Asset Management Ltd, left these positions at the end of October 2024 due to a serious illness. Koskimies passed away in November. Mikko was ...

Abstract: This paper proposes a blind equalization algorithm for dispersive wireless communication systems that employ high throughput quadrature amplitude modulation signals under both Gaussian and ...

7.2 MT @ 2.21% Cu Eq (Inf)). The objective of the first phase is to explore the eastward extension of the B-26 Zone to an average depth of approximately 400 metres, as well as providing access for ...

PRS Guitars today announced the continuation of its 40th anniversary celebration with two new models and several ...